SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neo-adjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)S. I. Rothschild,A. Zippelius,E. I. Eboulet,S. Savic,D. Betticher,A. Bettini,M. Fruh,M. Jorger,C. Britschgi, S. Peters,M. Mark,A. F. Ochsenbein,W. -D. Janthur,C. Waibel,N. Mach,M. Gonzalez, P. Frosch, G. Goddar,C. Rusterholz,M. PlessSWISS MEDICAL WEEKLY（2020）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
